{"id":129155,"date":"2023-01-24T15:19:56","date_gmt":"2023-01-24T15:19:56","guid":{"rendered":"https:\/\/ccs.ca\/?page_id=129155"},"modified":"2024-06-10T08:45:52","modified_gmt":"2024-06-10T12:45:52","slug":"mycovacc","status":"publish","type":"page","link":"https:\/\/ccs.ca\/fr\/mycovacc\/","title":{"rendered":"MYCOVACC"},"content":{"rendered":"\n
\u00c9tude nationale de surveillance active de la myocardite et de la p\u00e9ricardite suite \u00e0 l\u2019inoculation d\u2019un vaccin \u00e0 ARNm contre la COVID-19 (MYCOVACC) de la Soci\u00e9t\u00e9 cardiovasculaire du Canada (SCC)<\/h5>\n\n\n
\n
\"\"
Membres de l\u2019\u00e9quipe de l\u2019\u00e9tude MYCOVACC, de gauche \u00e0 droite : les Drs Peter Liu, Sean Virani et Michael McDonald, Meredith Wright, le Dr Tahir Kafil, Susanna Ogunnaike-Cooke, Carolyn Pullen et le Dr Nat Hawkins au Congr\u00e8s canadien sur la sant\u00e9 cardiovasculaire 2022 \u00e0 Ottawa.<\/figcaption><\/figure><\/div>\n\n\n

Communiqu\u00e9s de presse<\/mark><\/h3>\n\n\n\n